Data / Form D filings / Senti Biosciences Holdings, Inc.
Senti Biosciences Holdings, Inc.: Form D filings
Senti Biosciences Holdings, Inc., a biotechnology company in South San Francisco, CA, filed 2 Form D notices with the SEC between 2024 and 2026. The latest, on June 4, 2026, reports $10 million sold of a $40 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2 Corporate Drive, First Floor, South San Francisco, CA, 94080
- Phone
- (650) 239-2030
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1854270
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | New notice | $40,000,000 | $10,000,000 | $30,000,000 | 1 | May 20, 2026 | sec.gov |
| Dec 19, 2024 | New notice | $120,594,900 | $37,604,250 | $82,990,650 | 15 | Dec 9, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Timothy Lu | Executive Officer, Director | Chief Executive Officer of each Issuer and Director of Senti Biosciences Holdings, Inc. |
| Edward Mathers | Director | Director of Senti Biosciences Holdings, Inc. |
| Frances D. Schulz | Director | Director of Senti Biosciences Holdings, Inc. |
| Donald Tang | Director | Director of Senti Biosciences Holdings, Inc. |
| Brenda Cooperstone | Director | Director of Senti Biosciences Holdings, Inc. |
| James J. Collins | Director | Director of Senti Biosciences Holdings, Inc. |
| Feng Hsiung | Director | Director of Senti Biosciences Holdings, Inc. |
| Bryan Baum | Director | Director of Senti Biosciences Holdings, Inc. |
| Jay Cross | Executive Officer | Chief Financial Officer of Senti Biosciences Holdings, Inc. |
| Kanya Rajangam | Executive Officer | President, Head of Research and Development and Chief Medical Officer of Senti Biosciences Holdings, Inc. |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Jun 1, 2026 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Senti Biosciences Holdings, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.